Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) have been assigned an average recommendation of “Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $4.60.
CLSD has been the topic of a number of research reports. StockNews.com lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Clearside Biomedical in a report on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a research note on Tuesday, August 13th. Finally, Oppenheimer started coverage on Clearside Biomedical in a research report on Tuesday, June 25th. They issued an “outperform” rating and a $5.00 price target on the stock.
Read Our Latest Stock Analysis on CLSD
Institutional Trading of Clearside Biomedical
Clearside Biomedical Stock Down 2.0 %
CLSD stock opened at $1.00 on Wednesday. The stock has a market cap of $74.73 million, a price-to-earnings ratio of -1.82 and a beta of 2.43. Clearside Biomedical has a fifty-two week low of $0.65 and a fifty-two week high of $2.12. The business has a 50 day moving average price of $1.16 and a 200 day moving average price of $1.31.
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.25 million. During the same period last year, the company earned ($0.15) earnings per share. As a group, sell-side analysts anticipate that Clearside Biomedical will post -0.6 EPS for the current year.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
See Also
- Five stocks we like better than Clearside Biomedical
- How to Invest in Insurance Companies: A Guide
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What Does a Stock Split Mean?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Insider Trades May Not Tell You What You Think
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.